LETTER TO THE EDITOR

“PET scan contribution in chest tumors management: a systematic review for thoracic surgeons”

To the Editor: The paper by Duranti et al.1 “The PET contribution in chest tumors management: a systematic review for thoracic surgeons” was accurately investigated and discussed, concluding that the diagnostic benefits of FDG-PET are limited by false-positive results (the risk is around 10%)².

It is our opinion that another relevant pitfall of PET scan use in the modern staging of non-small cell lung carcinoma is represented also by the risk of a false-negative test. However, we saw in the references list of the excellent paper of Duranti et al. that only the papers by Nomori et al.³ and Verhagen et al.⁴ concerning this pitfall are mentioned.

The Leyn et al. suggested careful consideration about the reliability of PET scan for lymph node staging of non-small cell lung cancer. According to European Society of Thoracic Surgeons, the expected false-negative rate is about 10%⁵.

Al-Sarraf et al. reported two important data: a) higher incidence of occult mediastinal metastases after negative uptake of FDG-PET/CT scan⁶, and b) less sensitive staging by means of positron emission tomography in elderly patients with NSCLC⁷.

de Langen et al. emphasized the results of a recent meta-analysis with regard to this issue: a "post-test probability for N2 disease of 21% was found in patients with PET-negative nodes >16 mm⁸.

Silvestri et al. took in consideration this particular pitfall of PET scan use in modern staging of NSCLC and suggested other non-invasive procedures before proceeding directly to mediastinal thoracotomy⁹.

Gomez-Caro et al. observed that the false-negative rate for lymph node involvement was 14.4% and concluded that mediastinal staging by FDG-PET/CT may jeopardize accurate treatment for early stage NSCLC patients¹⁰.

In conclusion, considering these data as well as the important role of mediastinal staging in NSCLC and the FONICAP contribution as a case report¹¹, we suggest that a further excellent and analytical processing of the data recorded by an authoritative team of the Istituto Nazionale dei Tumori in Milan should be extended to the false-negative test, in part due probably to the biological characteristics of every single patient.

Franco Salvati
FONICAP - Forza Operativa Nazionale Interdisciplinare contro il Carcinoma Polmonare, Italy

References